Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia
ConditionBaseline Thrombocytopenia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMethodist Health System
About this trial
The use of clopidogrel as part of DAPT will be associated with lower bleeding rates compared to ticagrelor in patients with chronic thrombocytopenia requiring Percutaneous intervention (PCI )with Drug Eluting Stent (DES) or Bare Metal Stint(BMS).
Eligibility criteria
Qualifiers
≥ 18 years
PCI with either DES or BMS during study time period (April 1, 2018 through July 1 2021)
Thrombocytopenia defined as platelet count <100 x103 /µL on at least one occasion prior to PCI
At least one dose of DAPT post-PCI with aspirin and either clopidogrel or ticagrelor
Disqualifiers
Death within 48 hours post-PCI
DAPT prior to cardiac catheterization
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov